Regeneron Pharmaceuticals
REGN
$784.85
-0.58%
Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, and commercializes medicines across eye disease, cardiovascular disease, cancer, inflammation, and immunology, with a marketed portfolio anchored by Eylea/Eylea HD (partnered with Bayer), Dupixent (partnered with Sanofi), Libtayo, Praluent, Kevzara, and Lynozyfic. Regeneron is best characterized as a science-first, platform-driven large-cap biotech — its proprietary VelocImmune and related antibody technologies have generated one of the industry's most productive pipelines, and its economics are unusually leveraged to high-margin collaboration revenue from Sanofi and Bayer rather than to a single flagship product. The current investor narrative is dominated by two opposing forces: a sharp Phase 3 clinical trial failure in a key oncology combination that triggered a steep single-day selloff in May 2026, versus a subsequent powerful recovery driven by Dupixent's expanding label, Eylea HD conversion, and optimism around the broader immunology and oncology pipeline. With 27 analysts covering the name and a consensus Buy rating, the debate centers on whether Regeneron's roughly $22.4 billion consensus 2027 revenue estimate and pipeline optionality justify its premium multiple, or whether pipeline setbacks and Eylea biosimilar pressure warrant a more cautious stance.…
REGN
Regeneron Pharmaceuticals
$784.85
Related headlines
Investment Opinion: Should I buy REGN Today?
Rating: Buy. Regeneron offers a compelling risk/reward profile, trading at a forward PE of 12.95x with a consensus analyst target of $849.32 (8.2% upside) and a high target of $1,030 (31.2% upside). The company's 19% revenue growth, 31.4% net margin, and $4.16 billion in free cash flow support a premium valuation that the market has yet to fully recognize, making it an attractive GARP (Growth at a Reasonable Price) candidate.
The supporting evidence is robust: revenue grew 19.04% YoY in Q1 2026, gross margins are 85.4%, and operating margins are 24.9%. The balance sheet is fortress-like with a current ratio of 4.13 and debt-to-equity of 0.087. Free cash flow TTM of $4.16 billion provides ample resources for R&D and potential acquisitions. The forward PE of 12.95x is well below the sector average, and the PEG ratio of 3.38, while elevated, reflects the company's strong growth trajectory. Analyst sentiment is positive with a Buy consensus and a mean recommendation of 1.89.
The biggest risks are pipeline setbacks, Eylea biosimilar competition, and potential multiple compression if growth slows. The rating would upgrade to a strong Buy if the forward PE compresses below 12x or if pipeline data readouts are positive. It would downgrade to Hold if revenue growth decelerates below 10% or if another major Phase 3 trial fails. Relative to its history and peers, REGN appears undervalued on a forward earnings basis, offering a favorable entry point for long-term investors.
Sign up to view all
REGN 12-Month Price Forecast
Regeneron presents a favorable risk/reward profile, with a low forward PE of 12.95x that fails to reflect its 19% revenue growth and 31.4% net margin. The analyst consensus is Buy with an average target of $849, and the high target of $1,030 suggests significant upside if pipeline catalysts materialize. However, the May 2026 Phase 3 oncology failure and Eylea biosimilar risks warrant a medium confidence level. I would upgrade to high confidence if the company reports positive pipeline data or accelerates Eylea HD conversion, and downgrade if another major trial fails or revenue growth decelerates below 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $849.32 and implied upside of +8.2% versus the current price.
Average Target
$849.32
0 analysts
Implied Upside
+8.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$730 - $1030
Analyst target range
Bulls vs Bears: REGN Investment Factors
The bull case for Regeneron rests on its 19% revenue growth, fortress balance sheet, and deeply discounted forward PE of 12.9x, which suggests the market is undervaluing its high-margin immunology and eye-care franchises. The bear case centers on the May 2026 Phase 3 oncology failure, looming Eylea biosimilar competition, and a PEG ratio of 3.38 that implies high growth expectations are already baked in. Currently, the bull evidence appears stronger: the company's 31.4% net margin, 14.4% ROE, and $4.16 billion in free cash flow provide a solid foundation, while the analyst consensus Buy rating and $849 average target imply further upside. The single most important tension is whether Regeneron can successfully diversify its pipeline beyond Eylea and Dupixent; if the oncology setback proves isolated and new immunology data read out positively, the stock could re-rate toward the high target of $1,030. Conversely, if pipeline failures mount or Eylea erosion accelerates, the low multiple could prove justified.
Bullish
- Dupixent and Eylea HD drive 19% revenue growth: Q1 2026 revenue rose 19.04% YoY to $3.605 billion, with gross margin at 81.4% and operating margin at 17.8%. The top-line acceleration is being fueled by Dupixent's expanding label and Eylea HD conversion, which are high-margin products that should continue to scale.
- Analyst consensus Buy with 8.2% upside: 27 analysts rate REGN a Buy (mean 1.89) with an average target price of $849.32, implying 8.2% upside from the current $784.85. The high target of $1,030 suggests 31.2% upside if pipeline catalysts materialize.
- Forward PE of 12.9x is deeply discounted: REGN trades at a forward PE of only 12.95x and trailing PE of 17.92x, well below the broader biotech sector and its own historical average. This low multiple is especially striking given the company's 31.4% net margin and 14.4% ROE.
- Fortress balance sheet with 4.1x current ratio: The company carries debt-to-equity of just 0.087 and a current ratio of 4.13, providing substantial financial flexibility. Free cash flow TTM is $4.16 billion, easily covering the modest 8.2% payout ratio and funding R&D.
Bearish
- Phase 3 oncology failure crushed sentiment: A key cancer drug combination failed in Phase 3 in May 2026, triggering a steep single-day selloff that sent the stock from $698.25 on May 15 to $629.68 on May 18. This setback raises questions about the productivity of Regeneron's oncology pipeline and its ability to diversify beyond immunology and eye disease.
- Eylea biosimilar pressure looms large: Eylea and Eylea HD remain a major revenue contributor, but biosimilar competition is intensifying. The company's reliance on this franchise, combined with the need to convert patients to Eylea HD, creates meaningful revenue risk if conversion slows or pricing erodes.
- PEG ratio of 3.38 signals growth premium: Despite a low absolute PE, the PEG ratio of 3.38 indicates that the market is pricing in significant future growth. If earnings growth decelerates, the stock could face multiple compression, especially given the 2027 consensus revenue estimate of $22.4 billion.
- Recent relative underperformance vs. S&P 500: Over the past month, REGN has underperformed the S&P 500 by 5.70 percentage points (relative strength -5.70), and over the past six months it has lagged by 10.35 percentage points. This weak momentum could persist if pipeline setbacks continue.
REGN Technical Analysis
Beta
0.19
0.19x market volatility
Max Drawdown
-26.1%
Largest decline past year
52-Week Range
$541-$859
Price range past year
Annual Return
+31.1%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | -6.7% | -0.5% |
| 3m | +28.7% | +2.3% |
| 6m | +7.1% | +16.6% |
| 1y | +31.1% | +14.8% |
| ytd | +1.1% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Quarterly Revenue
$3.6B
2026-03
Revenue YoY Growth
+19.0%
YoY Comparison
Gross Margin
81.4%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Regeneron's financial risks are relatively contained but not negligible. The company carries debt-to-equity of only 0.087 and a current ratio of 4.13, indicating a strong liquidity position. However, its heavy reliance on collaboration revenue from Sanofi and Bayer means that any renegotiation or slowdown in those partnerships could disproportionately impact earnings. Additionally, R&D expenses are substantial—$1.65 billion in Q1 2026 alone—and must be sustained to drive future growth, which pressures near-term margins if revenue growth stalls. The trailing PE of 17.9x and forward PE of 12.9x suggest the market is not pricing in aggressive growth, but the PEG ratio of 3.38 indicates that earnings growth expectations are still elevated relative to the multiple.
Market and competitive risks are significant. Eylea, a key revenue driver, faces biosimilar competition that could erode pricing and market share. The May 2026 Phase 3 oncology failure highlights the inherent risks of drug development and raises doubts about the breadth of Regeneron's pipeline. With a beta of 0.193, the stock is less sensitive to broad market swings, but it is still exposed to sector-specific risks such as drug pricing reform and regulatory changes. Recent news of geopolitical tensions and inflation concerns could also weigh on biotech valuations, particularly for high-multiple names. The relative underperformance over the past month (-5.70% vs. S&P 500) suggests waning momentum that could persist if pipeline news disappoints.
In a worst-case scenario, a combination of Eylea biosimilar erosion, another major pipeline failure, and slower Dupixent growth could trigger a sharp decline. The 52-week low is $541, which represents a 31.1% downside from the current price of $784.85. The analyst low target of $730 implies a more modest 7.0% downside, but if sentiment deteriorates further, the stock could retest its 52-week low. The maximum drawdown over the past 180 days was -26.05%, indicating that a decline of that magnitude is plausible in a adverse scenario. Investors could lose 31% if the stock falls to its 52-week low, and even more if the bear case fully materializes.
FAQ
The key risks include pipeline failures, as evidenced by the May 2026 Phase 3 oncology setback, which could erode investor confidence and delay revenue diversification. Eylea biosimilar competition poses a threat to a major revenue source, potentially accelerating price erosion. Macroeconomic factors, such as drug pricing reform and inflation, could compress biotech valuations. Additionally, the company's reliance on collaboration revenue from Sanofi and Bayer introduces concentration risk. These risks are ranked from highest to lowest: pipeline failure, Eylea erosion, collaboration dependence, and macro headwinds.
The 12-month forecast includes a bull case (30% probability) targeting $900-$1,030, a base case (50%) targeting $800-$900, and a bear case (20%) targeting $541-$730. The base case is most likely, assuming steady revenue growth and no major pipeline failures. The key assumption is that Dupixent and Eylea HD continue to drive mid-to-high teens revenue growth, and the forward PE remains in the 13-15x range. The analyst average target of $849.32 aligns with the base case.
REGN appears undervalued on a forward earnings basis, trading at a forward PE of 12.95x and a trailing PE of 17.92x, both below the broader market and biotech peers. The PEG ratio of 3.38 suggests that growth expectations are already priced in, but the low absolute PE and 31.4% net margin indicate a discount. The market is paying a fair price for the company's current earnings but may be underestimating its pipeline potential. If the pipeline delivers, the stock could re-rate toward the analyst high target of $1,030, implying 31% upside.
REGN appears to be a good buy for long-term investors, given its forward PE of 12.95x, 19% revenue growth, and analyst consensus Buy rating with an average target of $849.32 (8.2% upside). The company's strong balance sheet, with $4.16 billion in free cash flow and a current ratio of 4.13, provides a margin of safety. However, the May 2026 Phase 3 oncology failure and Eylea biosimilar risks are significant overhangs. The stock is most suitable for investors with a medium to high risk tolerance and a time horizon of at least 2-3 years, who can withstand potential volatility from pipeline news.
REGN is more suitable for long-term investment due to its low beta (0.193), strong balance sheet, and pipeline-driven growth potential. The stock's volatility, as indicated by a max drawdown of -26.05% over the past 180 days, makes it less ideal for short-term trading. The company does not pay a significant dividend (yield 0.46%), so returns depend on capital appreciation. A minimum holding period of 2-3 years is recommended to allow pipeline catalysts to materialize and to ride out any near-term setbacks.